Compare Sana Biotechnology Inc (SANA) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Walmart Stores Inc — how do they compare? Sana Biotechnology Inc trades at $2.84 (market cap $836.71M), while Walmart Stores Inc trades at $111.32 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 1048.3× Sana Biotechnology Inc's market cap, and Walmart Stores Inc pays a 0.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Walmart Stores Inc for 101 Days on average.
| SANA | WMT | |
|---|---|---|
Market Cap | $836.71M | $877.15B |
Volume | 4,507,444 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $134.20 |
52-Week Low | $2.68 | $100.61 |
Typical Hold Time | 23 Days | 101 Days |
Enterprise Value | $749.96M | $939.38B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Walmart (WMT) trades at $108.11, up 0.82% today, with a neutral technical signal and strong fundamentals. Revenue grew to $681.0B in 2025, with net income rising to $19.4B and a 2.85% margin. The company has beaten EPS estimates for three consecutive quarters, and analyst consensus is a Buy with a $128.84 price target. Recent news highlights expansion in AI, e-commerce, and Medicare Advantage plans, supporting market share gains.
The outlook is positive due to consistent earnings beats, digital growth, and strategic initiatives, but risks include high valuation (P/E 40.06), rising costs, and economic sensitivity. Upside potential exists toward the consensus target, though near-term volatility may persist amid inflation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
